By: Ankit Shrivastava
After years of uncertainty, private equity (PE) in healthcare is making a strong comeback.
According to the Private Equity 2024 Year-In-Review and 2025 Outlook by Cherry Bekaert, healthcare deal activity soared to an estimated $104 billion in 2024, marking a resurgence after previous downturns. Several key trends are shaping the future of healthcare PE:
✅ Increased Deal Volume: Healthcare transactions saw a 17.7% YoY rise, with five megadeals exceeding $5B—a major leap from prior years. 💰
✅ Strategic Platform Investments: Fewer add-ons, but larger platform acquisitions dominated, signaling long-term growth bets.
✅ Regulatory Shifts & Policy Impact:
- 15 states now require regulatory approval for healthcare PE deals, adding complexity.
- Trump’s second term is expected to ease federal regulations, potentially unlocking new opportunities.
✅ Tech-Driven Growth: Digital health, biopharma, and healthcare IT continue to attract record investments.
With private equity dry powder at an all-time high, 2025 could witness even bigger moves in the healthcare sector. Will we see record exits and new platform investments?
Why Enventure is Positioned for Exit-Driven Deals in Healthcare PE
At Enventure, we specialize in value creation and operational due diligence, which are critical drivers for successful exits in healthcare PE. Our deep sector expertise and strategic approach uniquely position us to capitalize on the evolving exit market:
✔ Strategic Investments: Our focus on healthcare, biotech, and clinical research aligns with the most attractive PE exit opportunities.
✔ Operational Excellence: We drive efficiency, scalability, and profitability, making portfolio companies exit-ready.
✔ Strong Deal Flow: We leverage our network in the U.S. and India to identify high-value investment opportunities with clear exit pathways.
✔ Regulatory Expertise: We navigate complex healthcare regulations to position assets for high-value exits while mitigating risks.
✔ AI and Data-Driven Healthcare: We are betting on AI, precision medicine, and healthcare IT, sectors that are seeing rapid consolidation and M&A activity.
With exit values up 82% YoY, now is the time to focus on unlocking value and preparing for high-return divestitures. Enventure is at the forefront of this opportunity.
